Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC14815 GMX1778 (CHS828)

    N-[6-(4-氯苯氧基)己基]-N'-氰基-N''-4-吡啶基胍,GMX1778

    GMX1778 (CHS828) 是一种特异性的烟酰胺磷酸核糖转移酶(NAMPT)抑制剂。
  3. GC12003 VR23 A proteasome inhibitor
  4. GC16214 DEL-22379

    N-[2,3-二氢-3-[(5-甲氧基-1H-吲哚-3-基)亚甲基]-2-氧代-1H-吲哚-5-基]-1-哌啶丙酰胺

    An inhibitor of ERK dimerization
  5. GC16762 BMS-202

    PD1-PDL1抑制剂2, PD-1/PD-L1 inhibitor 2

    BMS-202是一种非肽性PD-1/PD-L1复合物抑制剂,与PD-L1隔离PD-1/PD-L1二聚体形成(IC50=53.6nM),以结合阻断人PD-1/PD-L1相互作用,从而抑制免疫反应抑制,从而阻止癌细胞逃避抗肿瘤免疫反应。
  6. GC15399 Dp44mT

    2-(二-2-吡啶基亚甲基)-N,N-二甲基肼基硫代甲酰胺

    An iron chelator with antiproliferative effects
  7. GC17425 Sodium Tauroursodeoxycholate (TUDC)

    牛磺熊去氧胆酸钠; Tauroursodeoxycholic acid sodium; TUDCA sodium; UR 906 sodium

    Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium 是一种内质网 (ER) 应激抑制剂。 Tauroursodeoxycholate 显着降低凋亡分子的表达,例如 caspase-3 和 caspase-12。 Tauroursodeoxycholate 也抑制 ERK。
  8. GC17828 BI-847325 A selective dual MEK/Aurora kinase inhibitor
  9. GC16278 A-1210477 A selective Mcl-1 inhibitor
  10. GC14488 NPS-1034

    2-(4-氟苯基)-N-[3-氟-4-[(3-苯基-1H-吡咯并[2,3-B]吡啶-4-基)氧基]苯基]-2,3-二氢-1,5-二甲基-3-氧代-1H-吡唑-4-甲酰胺

    A dual MET/AXL inhibitor
  11. GC16875 FLLL32

    (2E,2'E)-1,1'-环己基亚基二[3-(3,4-二甲氧基苯基)-2-丙烯-1-酮]

    An inhibitor of JAK2/STAT3 signaling
  12. GC15161 Calcium D-Panthotenate

    泛酸钙; Calcium pantothenate; Calcium D-pantothenate; Vitamin B5 calcium salt

    D-泛酸钙(维生素B5钙盐)是一种维生素,可以降低苹果汁中棒曲霉素的含量。
  13. GC18109 Astragaloside A

    黄芪甲苷

    Astragaloside A(黄芪甲苷A)是从黄芪中提取的活性皂苷化合物,具有抗氧化、心脏保护、抗炎、抗病毒、抗菌、抗纤维化、抗糖尿病和免疫调节的药理作用。
  14. GC10721 BDA-366

    1-[[(2S)-3-(二乙基氨基)-2-羟基丙基]氨基]-4-[[(2S)-2-环氧乙烷基甲基]氨基]-9,10-蒽醌

    A Bcl2-BH4 domain antagonist
  15. GC13442 Sanguinarine chloride

    氯化血根碱; Sanguinarin chloride; Sanguinarium chloride; Pseudochelerythrine chloride

    A natural alkaloid with anti-inflammatory and anti-oxidant properties
  16. GC12822 BML-210(CAY10433)

    NphenylN'(2Aminophenyl)hexamethylenediamide, CAY10433

    A potent, synthetic HDAC inhibitor
  17. GC17901 Tamoxifen

    他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen

    Tamoxifen(他莫西芬)是一种选择性雌激素受体调节剂 (SERM),可阻断乳腺细胞中的雌激素作用,并可激活不同组织细胞中的雌激素活性;Tamoxifen 还可以作为 Hsp90 激活剂,增强 Hsp90 分子伴侣 ATPase 的活性;Tamoxifen 还可以诱导 CreER(T2) 小鼠的基因敲除。
  18. GC12821 Oltipraz

    奥替普拉; RP 35972; NSC 347901

    A Nrf2 and CAR activator
  19. GC12074 BG45 A selective HDAC3 inhibitor
  20. GC12375 PF-4989216

    4-(4-氰基-2-氟苯基)-2-吗啉-5-(1H-1,2,4-三唑-5-基)噻吩-3-腈

    An orally bioavailable PI3K inhibitor
  21. GC13219 ONO-4059

    GS-4059 analog

    A derivative of ONO-4059
  22. GC14218 TP-0903

    TP-0903

    An Axl kinase inhibitor
  23. GC12387 Tiplaxtinin(PAI-039)

    ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸,PAI-039; Tiplasinin

    Tiplaxtinin(PAI-039)是一种口服生物利用的尿激酶型纤溶酶原激活物抑制剂-1(PAI-1)拮抗剂,IC50值为2.7μM。
  24. GC14681 Nolatrexed (AG-337)

    盐酸诺拉曲塞,AG 337; Thymitaq

    A thymidylate synthase inhibitor
  25. GC13526 Spautin-1

    Spautin-1抑制剂

    Spautin-1可抑制去泛素化酶USP10和USP13的活性,IC50值为0.6-0.7µM。
  26. GC16827 ELR510444 An inhibitor of tubulin polymerization
  27. GC14644 SBE 13 HCl A potent Plk1 inhibitor
  28. GC12222 Pexidartinib (PLX3397)

    培西达替尼,PLX-3397

    Pexidartinib(PLX3397) 是一种口服小分子酪氨酸激酶抑制剂,对集落刺激因子 1(CSF1) 受体 (IC50=20nM)、KIT 原癌基因受体酪氨酸激酶 (KIT)(IC50 = 10nM) 和类 FMS 酪氨酸激酶 3Pexidartinib 在体外是一种比伊马替尼更强的 KIT 抑制剂。
  29. GC15654 SBI-0206965

    SBI-0206965,这种嘧啶衍生物是一种高选择性的激酶ULK1抑制剂,IC50值为108nM。

  30. GC11140 Radotinib(IY-5511)

    拉多替尼

    A selective Bcr-Abl tyrosine kinase inhibitor
  31. GC16310 FTI 277 HCl FTI 277 HCl是一种强效且具有选择性的法尼基转移酶(FTase)抑制剂,IC50值为0.5nM,较香叶酰基香叶转移酶I(GGTase I)选择性高出约100倍。
  32. GC17916 Poziotinib

    波齐替尼

    An inhibitor of EGFRs
  33. GC14707 Purvalanol A

    NG-60

    A selective inhibitor of cyclin-dependent kinases
  34. GC10093 LY2409881

    IKK2抑制剂(LY2409881)

    A selective IKK2 inhibitor
  35. GC11547 MI-773 (SAR405838)

    MI-77301

    An inhibitor of MDM2-p53 protein-protein interactions
  36. GC16208 HO-3867 A selective STAT3 inhibitor
  37. GC13474 Garcinol

    山竹子素

    Garcinol是组蛋白乙酰转移酶p300和PCAF的非特异性抑制剂,IC50分别为7μM和5μM。

  38. GC15896 Z-Ile-Leu-aldehyde

    Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII

    Z-Ile-Leu-aldehyde (Z-IL-CHO) 是一种有效的、竞争性的 γ-分泌酶和缺口肽醛抑制剂。
  39. GC17008 (+)-Apogossypol

    變棉子酚,Apogossypol; NSC736630

    (+)-Apogossypol 是一种泛 BCL-2 拮抗剂。 (+)-Apogossypol 与 Mcl-1、Bcl-2 和 Bcl-xL 结合,EC50 分别为 2.6、2.8 和 3.69 μM。

  40. GC12902 Pyridoclax

    MR-29072

    Pyridoclax 是一种潜在的 Mcl-1 抑制剂。
  41. GC14631 SP2509

    HCI-2509, LSD1 Inhibitor VII

    A reversible inhibitor of LSD1
  42. GC11574 HPOB A potent and selective inhibitor of HDAC6
  43. GC12348 Ro 3306

    2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮

    Ro 3306是一种ATP竞争性抑制剂,主要靶向CDK1/cyclin B1(Ki值为35nmol/L)和CDK1/cyclin A复合物(Ki值为110nmol/L)。
  44. GC17262 Pifithrin-β

    5,6,7,8-四氢-2-(4-甲基苯基)-咪唑并[2,1-B]苯并噻唑,PFT β; Cyclic Pifithrin-α

    An inactivator of p53
  45. GC10021 CPI-360 A selective EZH2 inhibitor
  46. GC11784 LCZ696

    沙库必曲/缬沙坦; LCZ696

    A dual angiotensin II receptor antagonist and neprilysin inhibitor
  47. GC14794 PF-06463922

    劳拉替尼; PF-06463922

    PF-06463922是一种新型的、具有口服活性的ALK(IC50=15-113nM)和ROS1(Kis=0.025-0.7nM)双重抑制剂。
  48. GC15805 UMI-77 A selective Mcl-1 inhibitor
  49. GC12247 K-Ras(G12C) inhibitor 12 An allosteric inhibitor of oncogenic K-Ras(G12C)
  50. GC11973 HSP990 (NVP-HSP990)

    HSP-990

    An Hsp90 inhibitor
  51. GC16511 OTS964 A TOPK inhibitor

Items 2001 to 2050 of 2721 total

per page

Set Descending Direction